PATIENT VOICES IN RARE DISEASE HEALTH TECHNOLOGY ASSESSMENTS (HTA) RECENT TRENDS IN THE USE OF QUALITATIVE RESEARCH IN REIMBURSEMENT SUBMISSIONS TO CANADA'S DRUG AGENCY (CDA-AMC)

BACKGROUND

- Qualitative research can inform healthcare decision making by understanding lived experiences (particularly for rare diseases), assessing treatment acceptability and value, and supplementing quantitative data.¹
- Interest in how extensively qualitative research is used in healthcare decision making, specifically in HTA is expanding.²⁻⁵
- In Canada, sponsors of reimbursement submissions may submit qualitative evidence to HTAs – CDA-AMC and Institut national d'excellence en santé et services sociaux (INESSS).
- Additionally, these HTAs collect patient group input which often includes qualitative data.
- How extensively sponsors and patient groups are using qualitative evidence and what influence qualitative research has on reimbursement decisions remains unclear.

OBJECTIVE

To characterize the contemporary use of patient- or caregiver-centred qualitative research by sponsors and patient groups in Canadian reimbursement reviews of pharmaceuticals for rare diseases, with a focus on CDA-AMC.

METHODS

DATA EXTRACTION AND SYNTHESIS

- Sponsored reimbursement reviews of non-oncology pharmaceuticals for rare diseases, with recommendations issued in 2024, were retrieved from the CDA-AMC website in December 2024 and January 2025.⁶
 - Reimbursement reviews for oncology pharmaceuticals were excluded because of the inherent differences in their reimbursement submissions.
 - Rare diseases were defined as conditions affecting <1/2,000 as listed on orpha.net.⁷
- Qualitative research used or cited in the clinical review, pharmacoeconomic review, and patient group input report were extracted and synthesized.
- The following information was extracted:
 - Disease, pharmaceutical, and sponsor details.
- *De novo* qualitative research used.
- Additional qualitative research cited.
- Reimbursement recommendation and date issued. • *De novo* qualitative research was defined as
- qualitative methods used or qualitative data collected to support the submission.
- These studies and data were categorized using a published framework,¹ and the quality was assessed using the CASP checklist.⁸
- The corresponding reimbursement reviews conducted by INESSS in the province of Quebec were also reviewed.

GUIDELINE REVIEW

• Available information from CDA-AMC and INESSS on the use of qualitative research and patient involvement in reimbursement submissions was reviewed and summarized.

RESU

Ten CE

- De novo
- Two spectrum resear
- In SR0 the spo impact and in studies

- In SR07
 - 1. On thr
 - 2. And car
- Based used t (n=2), accept reach
- Of the qualita

Table 1. Summary of patient-based qualitative research in 10 rare disease HTA submissions to CDA-AMC

Project numbe

SR0721-000 SR0780-000

SR0799-000

SR0800-000

SR0798-000

SR0785-000

SR0793-000

SR0788-000

SR0801-000

SR0778-000

LTS							
DA-AMC reimbursement reviews were identified and reviewed (Table 1).							
qualitative research by sponsors	D	e no					
ponsors submitted <i>de novo</i> patient- or caregiver-centred qualitative rch (20%; Table 1).	•	ln a qua					
0799-000, Appendix 5, CDA-AMC cite a qualitative study, submitted by consor in their pharmacoeconomic evaluation, which explored disease cts and treatment effects through qualitative interviews with caregivers formed the selection of appropriate outcome measures for future es. ⁹	•	Dat tex Hot qua ana					
This study scored 9/10 on the CASP criteria.	•	Bas					
0788-000, two qualitative studies were included:							
ne assessed the content validity of clinical trial outcome measures rough qualitative interviews with patients and caregivers.	•	(n= On					
This study scored 8/10 on the CASP criteria. ¹⁰		suk					
nother explored disease impacts via interviews with patients and regivers, informing the disease background in the clinical review.							
This study did not include sufficient detail to assess its quality (abstract only). ¹¹							
on the CDA-AMC reimbursement reviews, it appears that the sponsors the qualitative research to: understand perspectives and provide context inform subsequent quantitative exercises (n=2), assess treatment tability and subjective value (n=1), reach groups other methods cannot (n=1), and contribute to economic model development (n=1; Figure 1).							
e ten corresponding INESSS reimbursement reviews, none detailed ative research included by the sponsors (0%).							
al qualitative research cited							

Additional qualitative research cited

• Two qualitative studies were used to understand perspectives and provide context in the disease background sections of the clinical review.^{12,13}

Pharmaceutical					De novo qualitative research				Date
	Disease	Generic	Brand	Sponsor	Submitted by sponsor	Submitted by patient group	qualitative research cited?	CDA-AMC recommendation	recommendation issued
)0	Chronic immune thrombocytopenia	avatrombopag	Doptelet	Sobi Canada, Inc.	No	Yes	No	Do not reimburse	08-May-24
0	Alagille syndrome	maralixibat	Livmarli	Mirum Pharmaceuticals Inc.	No	Yes	No	Reimburse with clinical criteria and/or conditions	22-Apr-24
0	Dravet syndrome	cannabidiol	Epidiolex	Jazz Pharmaceuticals Canada, Inc.	Yes ⁹	No	Yes ¹²	Reimburse with clinical criteria and/or conditions	18-Apr-24
)0	Lennox-Gastaut syndrome	cannabidiol	Epidiolex	Jazz Pharmaceuticals Canada, Inc.	No	No	No	Reimburse with clinical criteria and/or conditions	18-Apr-24
0	Seizures associated with Tuberous Sclerosis Complex	cannabidiol	Epidiolex	Jazz Pharmaceuticals Canada, Inc.	No	Yes	No	Reimburse with clinical criteria and/or conditions	18-Apr-24
0	Neuromyelitis optica spectrum disorder	ravulizumab	Ultomiris	Alexion Pharma GmbH	No	Yes	No	Reimburse with clinical criteria and/or conditions	13-Mar-24
0	Neuromyelitis optica spectrum disorders	inebilizumab	Uplizna	Horizon Therapeutics Canada	No	Yes	Yes ¹³	Reimburse with clinical criteria and/or conditions	13-Mar-24
0	Progressive familial intrahepatic cholestasis	odevixibat	Bylvay	Medison Pharma Canada Inc.	Yes ^{10,11}	Yes	No	Reimburse with clinical criteria and/or conditions	13-Feb-24
0	Hereditary transthyretin mediated amyloidosis	vutrisiran	Amvuttra	Alnylam Netherlands B.V.	No	Yes	No	Reimburse with clinical criteria and/or conditions	29-Jan-24
0	Homozygous familial hypercholesterolemia	evinacumab	Evkeeza	Ultragenyx Pharmaceutical Inc.	No	Yes	No	Reimburse with clinical criteria and/or conditions	12-Jan-24

Available information on qualitative research and patient involvement

• Methods guide: In March 2025, CDA-AMC released a new methods guide which provides some guidance on the use of qualitative research – gathered through formal qualitative studies or systematic reviews – to support elements of value.¹⁴ • **Patient leadership:** In December 2024, CDA-AMC appointed the first-ever patient member to its Figure 2. Patient voice in CDA-AMC submissions board of directors.¹⁵

• **Patient input:** CDA-AMC recently announced their plans to evolve the patient group input processes.^{16,17}

• **Deliberations:** This year, they published a new deliberative framework and launched the inclusion of a person with lived experience presentation in the deliberation committee meeting.^{18,19}

• **INESSS:** INESSS appointed a dedicated patient consultation professional in 2022.

• Their methodological guide recommends the use of qualitative data and patient input (via questionnaires and interviews) to inform evaluations.²⁰

novo qualitative research by patient groups


all reviews, patient groups provided input, eight of which included ualitative data from patients/caregivers (80%; Table 1).

bata presented included quotes from interviews, social media posts, and freeext responses in surveys.

owever, there was little methodological information provided to assess the uality of these data collection methods, and no indication that qualitative nalysis methods were applied.

ased on the patient input reports, it appears that the patient groups used nese qualitative data to: assess treatment acceptability and subjective value n=8); and understand perspectives and provide context (n=6; Figure 1).

nly four (40%) INESSS reimbursement reviews included qualitative data ubmitted by patient groups.



Abbreviation: HTA, Health technology assessment



Abbreviation: PWLE, Persons with lived experience





HTA10

LIMITATIONS

- We relied on the information included by CDA-AMC and INESSS in their reimbursement reviews which may not fully describe the qualitative evidence submitted by sponsors in their submissions.
- The impact of including high quality patient-based research on reimbursement decisions cannot be determined from this work and requires further investigation.

CONCLUSION

- Few sponsors submitted patient- or caregiver-centred qualitative evidence; however, CDA-AMC received qualitative data from patient groups to consider for most submissions.
- Limited inclusion of qualitative research by sponsors may be explained by the absence of clear guidance from decisionmakers on its use and benefits to HTA.
- While qualitative data submitted by patient groups provide important insight into patient priorities and values, these data could be strengthened by the inclusion of greater methodological detail.
- HTA processes in this area are evolving, and experts (such as the Health Economics Methods Advisory) could play a key role in developing future guidance for sponsors and patient groups.²¹

REFERENCES

- Szabo SM, Hawkins NS, Germeni E. Int J Technol Assess Health Care. 2024;40(1):e6.
- 2. Lewin S, Glenton C. Int J Equity Health. 2018;17(1):126. 3. Germeni E, Szabo S. Int J Technol Assess Health Care. 2023;39(1):e23.
- 4. FDA PFDD Guidance. Accessed Nov 7, 2024. https://www.fda.gov/drugs/developmentapproval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancingincorporation-patients-voice-medical.
- 5. Booth A. DSU Report. 2020. Accessed May 1, 2025. https://www.sheffield.ac.uk/nicedsu/methods-development/chte2020-qualitative-evidence.
- CDA-AMC. Reimbursement Review Reports. Accessed May 1, 2025. https://www.cdaamc.ca/reimbursement-review-reports.
- 7. Orphanet. Accessed May 1, 2025. https://www.orpha.net/. CASP. CASP Checklist: CASP Qualitative Studies Checklist. Accessed April 30, 2025.
- https://casp-uk.net/casp-tools-checklists/gualitative-studies-checklist/
- 9. Marshall J, Skrobanski H, Moore-Ramdin L, et al. J Child Neurol. 2023;38(6–7):394–406 10. Gwaltney C, Bean S, Venerus M, et al. Adv Ther. 2022;39(11):5126–5143.
- 11. Torfgard K, Gwaltney C, Paty J, et al. J Pediatr Gastroenterol Nutr. 2018;66(Suppl 2):813–814.
- 12. Juandó-Prats C, James E, Bilder DA, et al. Epilepsy Behav. 2021;122:108198. 13. Mutch K, Methley A, Hamid S, et al. Disabil Rehabil. 2017;39(13):1279–1286.
- 14. CDA-AMC. Methods Guide. Accessed April 30, 2025. https://www.cda-amc.ca/methods-
- guide. 15. CDA-AMC. Maureen Smith. Accessed April 30, 2025. https://www.cda-amc.ca/maureensmith
- 16. CDA-AMC. Patient Organization Preconsultation Enhancing the Drug Reimbursement
- Review Process. Accessed April 30, 2025. https://www.youtube.com/watch?v=zVzCelipf_w. 17. CDA-AMC. Expert Committee Deliberation at Canada's Drug Agency. Accessed May 1, 2025 https://www.cda-
- amc.ca/sites/default/files/MG%20Methods/expert_committee_deliberation.pdf. 18. CDA-AMC. News: Evolving the Patient Group Input Process in Drug Reimbursement Reviews.
- Accessed May 1, 2025 https://www.cda-amc.ca/news/evolving-patient-group-input-processdrug-reimbursement-reviews-0. 19. CDA-AMC. Guidance for Providing Patient Input. Accessed May 1, 2025. https://www.cda-
- amc.ca/sites/default/files/Drug_Review_Process/Guidance%20for%20Providing%20Patient %20Input.pdf.
- 20. INESSS. Guide méthodologique. Consultation des patients, des usagers, des personnes proches aidantes et des associations de patients dans les travaux d'évaluation. Accessed May 1, 2025.
- https://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Processus/INESSS _Guide_metho_Consultation_patient_DER_240612.pdf.
- 21. CDA-AMC. News: ICER, NICE, and Canada's Drug Agency Convene the Health Economics Methods Advisory. Accessed May 1, 2025. https://www.cda-amc.ca/news/icer-nice-andcanadas-drug-agency-convene-health-economics-methods-advisory.

DISCLOSURES

FUNDING: None to report **DISCLOSURES:** None to report **CONTACT: jdunne@broadstreetheor.com**

Scan QR code to download a copy of this poster

